Lupus Anticoagulant Testing Market Report and Forecast 2025-2034

The global lupus anticoagulant testing market was valued at USD 620.10 Million in 2024 driven by the rising prevalence of autoimmune disorders across the globe. It is expected to grow at a CAGR of 5.72% during the forecast period of 2025-2034 and attain a market value of USD 1081.52 Million by 2034.

Lupus Anticoagulant Testing Market Overview

Lupus anticoagulant (LA) testing is essential for diagnosing antiphospholipid syndrome (APS) and related autoimmune disorders. Key drivers in the market include the rising prevalence of autoimmune conditions like APS and advancements in diagnostic technologies. Trends such as the adoption of advanced assay systems and innovations like hexagonal phase phospholipid assays enhance test accuracy and efficiency. These factors, coupled with increasing demand for precise diagnostics, are propelling the market, supporting advancements in personalized and preventive healthcare.

Lupus Anticoagulant Testing Market Growth Drivers

Rising Prevalence of Autoimmune Disorders Drives Market Growth

Autoimmune conditions, such as systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), are becoming increasingly common. This rise is creating a greater demand for precise lupus anticoagulant testing. The National Health Council reports that around 50 million people in the United States are living with autoimmune disease, with an annual increase of 3-12%. These statistics highlight the urgent demand for early and reliable diagnostic tools to help manage these conditions effectively.

Lupus Anticoagulant Testing Market Trends

Several trends and developments are being observed in the market to enhance the current situation. The following are some of the noteworthy trends.

Advancements in Diagnostic Panels

The evolution of diagnostic panels in recent years has significantly enhanced the accuracy and efficiency of lupus anticoagulant testing, a key factor in managing anticoagulant-related complications. As the demand for precise and comprehensive testing increases, innovative solutions are carving new pathways in the market. For instance, in February 2024, ARUP Laboratories launched an updated reflexive panel that detects and neutralizes commonly prescribed anticoagulant medications, reducing their impact on test results. Such innovations improve diagnostic accuracy and streamline testing processes, aligning with the increasing demand for personalized medicine, thus significantly advancing the market in response to evolving healthcare needs.

Increased R&D Initiatives Poised to Elevate Lupus Anticoagulant Testing Market Value

In February 2024, researchers emphasized the importance of enhancing lupus anticoagulant (LA) testing for the effective management of antiphospholipid syndrome (APS). They advocated for a standardized approach to LA testing, which ensures greater consistency and reliability in diagnosis. Such advancements aim to optimize diagnostic accuracy, improve patient outcomes, and support the evolving demands in rheumatology, contributing positively to healthcare advancements.

Adoption of Advanced Assay Systems to Drive Lupus Anticoagulant Testing Market Growth

The adoption of advanced assay systems has become one of the trends in the market. These innovative technologies enhance testing accuracy and streamline laboratory workflows, ultimately leading to improved patient outcomes. For instance, in July 2024, Dynacare replaced the current platelet neutralization procedure with Hex-LA, a cutting-edge hexagonal phase phospholipid assay. This integrated test combined screening, confirmatory, and mixing steps into a single system, improving simplicity and sensitivity in compliance with ISTH and CLSI guidelines.

Growing Focus on Point-of-Care Testing (POCT) to Elevate Lupus Anticoagulant Testing Market Demand

The increasing demand for rapid and on-site testing solutions is driving innovation in point-of-care testing for lupus anticoagulants. POCT offers several advantages, including faster results, improved patient management, and greater accessibility in various healthcare settings. This trend aims to enhance patient care by facilitating timely diagnosis and monitoring of antiphospholipid syndrome and related conditions.

Lupus Anticoagulant Testing Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Test Type

• Prothrombin Time (PT)
• Activated Partial Thrombopl Time
• Dilute Russell's Viper Venom Time
• Coagulation Factor VIII Assay
• Others

Market Breakup by End User

• Hospitals
• Clinics
• Diagnostic Laboratories
• Others

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Lupus Anticoagulant Testing Market Share

Market Share by End User Set to Witness Significant Growth

Based on end users, the market is divided into hospitals, clinics, diagnostic laboratories, and others. Among these, hospitals are expected to dominate the market due to their extensive patient base and advanced infrastructure. Owing to increasing outpatient services and rising demand for timely diagnoses, diagnostic laboratories are expected to witness significant growth in order to enhance healthcare accessibility and efficiency. As a result, this segment will drive overall market growth in the forecast period.

Lupus Anticoagulant Testing Market Analysis by Region

Based on region, the market report covers North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Among these, North America is expected to dominate the market due to the well-developed healthcare infrastructure, rising research investments in blood clotting disorders, and increasing prevalence of autoimmune disorders like systemic lupus erythematosus disease. Furthermore, the high healthcare spending and increased government funding are expected to boost the market growth in the region.

Leading Players in the Lupus Anticoagulant Testing Market

The key features of the market report include patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:

Laboratory Corporation of America Holdings

Established in 1971 and headquartered in North Carolina, USA, Laboratory Corporation of America Holdings (Labcorp) offers comprehensive diagnostic testing services. Its lupus anticoagulant (LA) testing portfolio includes advanced coagulation assays and reflexive panels designed to provide accurate LA detection, aiding in the diagnosis and management of antiphospholipid syndrome and related conditions.

Associated Regional and University Pathologists, Inc.

Founded in 1984 and based in Utah, United States, ARUP Laboratories is a leading reference laboratory. It provides updated lupus anticoagulant reflexive panels, integrating innovative technologies such as hexagonal phase phospholipid assays, enhancing test accuracy by mitigating interference from anticoagulant medications.

Quest Diagnostics Incorporated

Established in 1967 and headquartered in New Jersey, United States, Quest Diagnostics offers lupus anticoagulant testing services through its specialized coagulation test panels. These include comprehensive screening and confirmatory assays aligned with international guidelines to ensure precise detection and support accurate diagnosis of antiphospholipid syndrome.

Precision Biologics Inc.

Founded in 2012 and based in Vancouver, Canada, Precision Biologics specializes in developing diagnostic solutions. Its lupus anticoagulant testing products focus on high-sensitivity assays, providing efficient and reliable detection methods for healthcare providers managing thrombotic disorders and autoimmune conditions like antiphospholipid syndrome.

Other companies include Ulta Lab Tests LLC, Diagnostica Stago Inc., and F. Hoffmann-La Roche Ltd.

Key Questions Answered in the Global Lupus Anticoagulant Testing Market

• What was the global lupus anticoagulant testing market value in 2024?
• What is the global lupus anticoagulant testing market forecast outlook for 2025-2034?
• What are the regional markets covered in the EMR report?
• What is the market segmentation based on the testing market?
• What is the market segmentation based on the end user?
• What are the major factors aiding the global lupus anticoagulant testing market demand?
• What are the market's major drivers, opportunities, and restraints?
• Which regional market is expected to lead the market share in the forecast period?
• Which country is expected to experience expedited growth during the forecast period?
• What are the major global lupus anticoagulant testing market trends?
• How does the rise in the geriatric population impact the market size?
• Who are the key players involved in the global lupus anticoagulant testing market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?